Boston Scientific Corporation
BSX
Rang in aandelen
#409
Deze bedrijfsbeschrijving is alleen in het Engels beschikbaar.
Boston Scientific Corporation (BSX) operates as a global leader in medical... Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, cardiac resynchronization therapy devices, and pacemakers, complemented by remote patient management systems. Furthermore, Boston Scientific offers sophisticated technologies for diagnosing and treating complex heart rate and rhythm irregularities. These encompass 3-D cardiac mapping and navigation tools, along with a suite of specialized catheters (including ablation, diagnostic, mapping, and intracardiac ultrasound types), delivery sheaths, and related accessories. Its offerings also extend to neurological conditions, providing spinal cord stimulator systems for chronic pain management, indirect decompression systems, and deep brain stimulation systems. In the realm of interventional cardiology, the company's innovations include drug-eluting coronary stent systems designed for treating coronary artery disease, products for percutaneous coronary interventions to combat atherosclerosis, and intravascular imaging catheters (such as ultrasound and fractional flow reserve devices) for assessing coronary arteries, heart chambers, and peripheral vessels. It also develops structural heart therapies. Beyond this, Boston Scientific supplies an array of stents, balloon catheters, wires, and atherectomy systems for the treatment of arterial diseases. For venous conditions, it provides thrombectomy and acoustic pulse thrombolysis systems, alongside wires and stents. Critically, the company also contributes to cancer treatment through peripheral embolization devices, radioactive microspheres, various ablation systems (including cryotherapy), and micro and drainage catheters. The organization was established in 1979 and maintains its corporate headquarters in Marlborough, Massachusetts.
Aandeelprijs
$41.88
Laatst gesynchroniseerd: 2026-10-30
Marktkapitalisatie
$60.69B
Verandering (1 dag)
-1.89%
Verandering (1 jaar)
-58.42%
Land
US
Aandelendata: Financial Modeling Prep·Bijgewerkt op ·Geen beleggingsadvies·Zo rekenen we
Handel Boston Scientific Corporation (BSX)
Categorie
Healthcare
P/B-ratio voor Boston Scientific Corporation (BSX)
P/B-ratio op November 2026 TTM: 2.44
Volgens de meest recente financiële rapporten en aandelenkoers van Boston Scientific Corporation is de huidige P/B-ratio (TTM) 2.44. Eind 2025 had het bedrijf een P/B-ratio van 5.83.
P/B-ratiohistoriek voor Boston Scientific Corporation van 2000 tot 2026
P/B-ratio aan het einde van elk jaar
| Jaar | P/B-ratio | Verandering |
|---|---|---|
| 2026 (TTM) | 2.44 | -58.16% |
| 2025 | 5.83 | -3.52% |
| 2024 | 6.04 | 38.59% |
| 2023 | 4.36 | 15.67% |
| 2022 | 3.77 | 3.62% |
| 2021 | 3.63 | 9.38% |
| 2020 | 3.32 | -26.72% |
| 2019 | 4.53 | -18.94% |
| 2018 | 5.59 | 15.46% |
| 2017 | 4.84 | 11.08% |
| 2016 | 4.36 | 12.58% |
| 2015 | 3.87 | 51.08% |
| 2014 | 2.56 | 4.01% |
| 2013 | 2.47 | 110.13% |
| 2012 | 1.17 | 65.28% |
| 2011 | 0.71 | -30.21% |
| 2010 | 1.02 | -7.80% |
| 2009 | 1.10 | 24.98% |
| 2008 | 0.88 | -22.93% |
| 2007 | 1.15 | -19.92% |
| 2006 | 1.43 | -69.73% |
| 2005 | 4.73 | -36.01% |
| 2004 | 7.39 | -30.56% |
| 2003 | 10.64 | 52.20% |
| 2002 | 6.99 | 40.54% |
| 2001 | 4.97 | 73.37% |
| 2000 | 2.87 | 0.00% |
P/B-ratio voor vergelijkbare bedrijven of concurrenten
| Bedrijf | P/B-ratio | Verschil in P/B-ratio | Land |
|---|---|---|---|
| 3.6116 | 48.05% |
US
|
|
| 2.4596 | 0.82% |
IE
|
|
| 4.7555 | 94.94% |
US
|
|
| 2.513 | 3.01% |
DE
|
|
| 4.9948 | 104.75% |
US
|
Vragen over de P/B-verhouding van Boston Scientific Corporation
Wat is de P/B-verhouding van Boston Scientific Corporation?
Per nov. 2026 bedraagt de P/B-verhouding van Boston Scientific Corporation 2.44.
Wat was de P/B-verhouding van Boston Scientific Corporation in 2025?
In 2025 bedroeg de P/B-verhouding van Boston Scientific Corporation 5.83, tegenover 6.04 in 2024.
Hoe heeft de P/B-verhouding van Boston Scientific Corporation zich sinds 2020 ontwikkeld?
Tussen 2020 en 2025 was de P/B-verhouding van Boston Scientific Corporation het hoogst in 2024 (6.04) en het laagst in 2020 (3.32).
Hoe verhoudt de P/B-verhouding van Boston Scientific Corporation zich tot vergelijkbare bedrijven?
Bij Boston Scientific Corporation is de P/B-verhouding (2.44) lager dan bij alle 5 vergelijkbare bedrijven in de lijst hierboven. Van die bedrijven heeft Edwards Lifesciences Corporation de hoogste waarde: 4.99.